The effect of Empagliflozin on Glucagon, Beta hydroxybutyrate and insulin levels in type 2 diabetic patients

Assessment of serum levels of Beta hydroxybutyrate, Glucagon, Cortisol and Insulin before and after one month treatment with Empagliflozin in comparison with Metformin in type 2 diabetic patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210730052022N1

Enrollment

Registered

2021-11-15

Start date

2021-09-23

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: patients with type 2 diabetes who received Metformin for at least three months but their HbA1c is greater than 7 to 9%. They will receive 10 miligram tablets of Emp

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients Thirty year old or more Uncontrolled blood sugar after at least 3 months treatment with Metformin

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Renal failure (Glomerular Filtration Rate (GFR) less than 45 milliliters per minute) Previous history of diabetic ketoacidosis (DKA) Previous history of amputation due to diabetes Consumption of drugs that affect the parameters of study

Design outcomes

Primary

Measure	Time frame
Serum level of Beta hydroxybutyrate. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Colorimetric assay using Randox kit with autoanalyzer.;Serum level of Glucagon. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Enzyme Linked Immunosorbent Assay (ELISA) method.;Serum level of Cortisol. Timepoint: Before strarting and then one month after treatment with Empagliflozin. Method of measurement: Radioimmunoassay (RIA) method.;Serum level of Insulin. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Radioimmunoassay (RIA) method.	—

Measure

Time frame

Serum level of Beta hydroxybutyrate. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Colorimetric assay using Randox kit with autoanalyzer.;Serum level of Glucagon. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Enzyme Linked Immunosorbent Assay (ELISA) method.;Serum level of Cortisol. Timepoint: Before strarting and then one month after treatment with Empagliflozin. Method of measurement: Radioimmunoassay (RIA) method.;Serum level of Insulin. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Radioimmunoassay (RIA) method.

—

Secondary

Measure	Time frame
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). Timepoint: Before and then one month after treatment with Empagliflozin. Method of measurement: Calculation using blood sugar and Insulin levels in fasting state.;Weight. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Scale.;Body Mass Index (BMI). Timepoint: Before starting and then after one month treatment with Empagliflozin. Method of measurement: Calculation using weight and height.;Fasting Blood Sugar (FBS). Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Colorimetric method with autoanalyzer.;Blood pressure. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Sphygmomanometer.;Glycated Hemoglobin (HbA1c). Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: High-Perforrmance Liquid Chromatography (HPLC).	—

Measure

Time frame

Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). Timepoint: Before and then one month after treatment with Empagliflozin. Method of measurement: Calculation using blood sugar and Insulin levels in fasting state.;Weight. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Scale.;Body Mass Index (BMI). Timepoint: Before starting and then after one month treatment with Empagliflozin. Method of measurement: Calculation using weight and height.;Fasting Blood Sugar (FBS). Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Colorimetric method with autoanalyzer.;Blood pressure. Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: Sphygmomanometer.;Glycated Hemoglobin (HbA1c). Timepoint: Before starting and then one month after treatment with Empagliflozin. Method of measurement: High-Perforrmance Liquid Chromatography (HPLC).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArash Arya

Shiraz University of Medical Sciences

arya91842@yahoo.com+98 71 3228 6403

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026